Rodman & Renshaw initiates coverage on Cellect Biotechnology (NASDAQ: APOP) with a Buy rating and a price target of $10 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE